Inflammatory Myopathy
26
13
13
3
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 26 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (26)
BCMA-CD19 cCAR-T for the Treatment of Refractory Inflammatory Myopathy
UCAR T-cell Therapy Targeting CD19/ BCMA(QT-019C) in Patients With Relapse/ Refractory Autoimmune Diseases
Virtual Reality and Robotics in Inflammatory Myopathy Rehabilitation
An Exploratory Clinical Study of YTS109 Cell for R/R Autoimmune Diseases
A Clinical Study of YTS109 Cells for the Treatment of R/R Autoimmune Diseases
A Clinical Study of YTS109 Cell for R/R Autoimmune Diseases
Exploratory Clinical Study on YTS109 Cell Therapy for Autoimmune Diseases
A Clinical Study of TI-0032-III Injection in Patients With Relapsed and Refractory Autoimmune Diseases
MIHRA - Patient-Rooted Insights for Shaping Myositis Science (PRISMS)
TELITACICEPT IN INFLAMMATORY MYOPATHIES(TELITACICEPT-IM)
CAR T-cell Therapy Targeting CD19 and BCMA in Patients With Relapse/Refractory Autoimmune Diseases
A Clinical Study of YTS109 Cell in R/R Autoimmune Diseases
UCAR T-cell Therapy Targeting CD19/ BCMA in Patients With Relapse/ Refractory Autoimmune Diseases
BCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases
Renal Manifestations During Idiopathic Inflammatory Myopathies
Universal CAR-T Cells (BRL-301) in Relapse or Refractory Autoimmune Diseases
An Clinical Study of YTS109 Cell Injection in Subjects With Recurrent/Refractory Autoimmune Disease
The Safety and Efficacy of Anti-CD19 CAR-T Cells in Patients With Relapsed/Refractory Autoimmune Diseases
Anti-CD19-CD3E-CAR-T Cells in Relapsed/Refractory Autoimmune Disease
Adult Idiopathic Inflammatory Myopathy With Cardiac Injury